KYMR

KYMR

USD

Kymera Therapeutics Inc. Common Stock

$60.670+4.870 (8.728%)

リアルタイム価格

Healthcare
バイオテクノロジー
米国

価格チャート

Loading Chart...

主要指標

市場指標
企業ファンダメンタルズ
取引統計

市場指標

始値

$55.800

高値

$61.580

安値

$55.660

出来高

0.77M

企業ファンダメンタルズ

時価総額

4.3B

業種

バイオテクノロジー

United States

取引統計

平均出来高

0.75M

取引所

NGM

通貨

USD

52週レンジ

安値 $19.445現在値 $60.670高値 $63.96

関連ニュース

Analyst Upgrades

Guggenheim Assumes Kymera Therapeutics at Buy, Announces Price Target of $90

Guggenheim analyst Brad Canino assumes Kymera Therapeutics with a Buy rating and announces Price Target of $90.

もっと見る
Guggenheim Assumes Kymera Therapeutics at Buy, Announces Price Target of $90
GlobeNewswire

Kymera Therapeutics to Participate in Upcoming November Investor Conferences

WATERTOWN, Mass., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ:KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological

もっと見る
Kymera Therapeutics to Participate in Upcoming November Investor Conferences
GlobeNewswire

Kymera Therapeutics Presents New Preclinical Data for KT-579, a First-in-Class, Oral IRF5 Degrader, at the American College of Rheumatology Annual Meeting

KT-579, a potent, selective, oral degrader of IRF5, demonstrated broad activity across multiple preclinical models of lupus and rheumatoid arthritis (RA), with activity comparable or superior to approved and clinically

もっと見る
Kymera Therapeutics Presents New Preclinical Data for KT-579, a First-in-Class, Oral IRF5 Degrader, at the American College of Rheumatology Annual Meeting
Analyst Upgrades

BTIG Maintains Buy on Kymera Therapeutics, Raises Price Target to $75

BTIG analyst Jeet Mukherjee maintains Kymera Therapeutics with a Buy and raises the price target from $59 to $75.

もっと見る
BTIG Maintains Buy on Kymera Therapeutics, Raises Price Target to $75
Analyst Upgrades

Mizuho Initiates Coverage On Kymera Therapeutics with Outperform Rating, Announces Price Target of $81

Mizuho analyst Joseph Catanzaro initiates coverage on Kymera Therapeutics with a Outperform rating and announces Price Target of $81.

もっと見る
Mizuho Initiates Coverage On Kymera Therapeutics with Outperform Rating, Announces Price Target of $81

最新情報を入手

価格アラートを設定し、AI分析の更新とリアルタイム市場ニュースを受け取る。